Novo Nordisk A/s

Daniele Granata

Marie-Ange Buyse

Soren Steffensen

Frantisek Hubalek

Mathias Norrman

Evelyn De Tavernier

Jais Rose Bjelke

Thomas Egebjerg

Per J Greisen

Andreas Vegge

Philip Jonas Sassene

Jacob Lund

Simone Fulle

The present invention provides ISVD polypeptide derivatives capable of binding coagulation Factor IX(a) and Factor X(a) which are highly potent and provide a sufficiently long half-life such to allow for effective subcutaneous—as well as peroral administration. The ISVD polypeptides derivatives disclosed herein are thus suitable for treatment of haemophilia A, haemophilia A with inhibitors and acquired haemophilia A by various routes of administration including subcutaneous and peroral administration.

Highly potent ISVD compounds capable of substituting for FVIII(A)

Growing community of inventors

Copenhagen, Denmark

Daniele Granata